| Latest Posters
|
MitoProd patented technology for RNA manufacturing and its novel circular interfering RNA
Jérome Lacoste*, Guillaume Plane*, and Jean-Paul Di Rago** , * MitoProd SA, 146 rue Léo Saignat, 33076 Bordeaux, France - ** CNRS (Centre National de la Recherche Scientifique), Bordeaux, France
Here is a description of MitoProd patented technology for RNA manufacturing, permitting a recurring production of RNA in industrial quantities. This technology enables the production of custom RNA at a gram scale, 99 % full length and 95% pure. MitoProd has also designed a new class of interfering RNA called ciRNA®, which have improved features such as RNAses resistance and an increased in vivo efficiency compared to siRNAs.
|
|
|
|
MicroRNA-23b negatively regulates urokinase and c-met and inhibits migration of human hepatocellular carcinoma cells.
Salvi A, Sabelli C, Moncini S, Venturin M, Arici B ,Riva P, Portolani N, Giulini SM, Barlati S and De Petro G., University of Brescia
By bioinformatics we predicted that miR-23b could recognize two sites in the 3’ UTR of uPA (urokinase-type plasminogen activator) and four sites in the 3’ UTR of c-met (hepatocyte growth factor receptor). miR-23b transfections in SKHep1C3 caused uPA and c-met decreased and migration and proliferation inhibition of SKHep1C3; anti-miR-23b transfection in human fibroblasts upregulated uPA and c-met. uPA and c-met shared a common microRNA that negatively regulates their expression.
|
|
|
|
Profiling formalin-fixed, paraffin-embedded (FFPE) samples on three Agilent microarray platforms
Grazyna Fedorowicz, Srinka Ghosh, Steve Guerrero, Thomas Wu, and Zora Modrusan, Genentech
Thousands of formalin-fixed, paraffin-embedded (FFPE) samples from clinical archives are available for retrospective studies. Such samples could provide crucial information for drug target discovery and diagnostics of various diseases. Here we used FFPE samples and their matched fresh-frozen (FF) counterparts to examine their performance on three types of microarrays including whole genome expression, comparative genomic hybridization (CGH) and microRNA.
|
|
|
|
Evaluation of a Novel Approach for the Measurement of RNA Quality
Timothy Wilkes; Alison Devonshire; Carole Foy, LGC Limited
The potential medical applications of microarrays have generated much interest, within the biomedical community. Numerous potential sources of variation have raised concerns regarding assay consistency and data quality. Previous studies have highlighted RNA integrity as having a major effect on data quality. We describe here a comparison of the performance characteristics of the Agilent (Bioanalyser) and Lab901 (Screen Tape System) platforms, and their capacity to determine sample RNA integrity.
|
|
|
|
Intended transcriptional gene silencing with siRNA to the human Vascular Endothelial Growth Factor (VEGF) promoter results in VEGF repression through sequence-specific off-targeting
Joshua Moses, Amber Goodchild and Laurent Rivory, School of Biotechnology & Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia; Eli Lilly Pty. Ltd., West Ryde, NSW, Australia
SiRNA designed to target the human VEGF gene promoter revealed a putative candidate for transcriptional gene silencing. However, mutation or deletion of the target site demonstrated that the observed VEGF knockdown was the result of a sequence-specific off-target effect. Bioinformatic and microarray analyses of genes implicated in VEGF transcriptional control followed by knockdown and Western blotting experiments presented one candidate, GRB2, as an unintended target of the VEGF promoter-specifi
|
|
|
|
A Web Interface for Automatic Microarray Analysis
Enrico Glaab, Jonathan M. Garibaldi, Natalio Krasnogor, Nottingham University
DNA-Microarray technology provides a diagnostic tool for studying cancer and genetic diseases, allowing the experimenter to identify disease related genes and predict the tumour type for new cell samples. However, the statistical analysis of microarray data is a time-consuming and error-prone process. To address this problem we have developed a web interface for automatic DNA-microarray analysis, ArrayMining.net, which guides the user through the analysis process and performs automatic parameter
|
|
|
| |
|